1. Home
  2. RXO vs ADPT Comparison

RXO vs ADPT Comparison

Compare RXO & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RXO Inc.

RXO

RXO Inc.

HOLD

Current Price

$24.70

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.01

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXO
ADPT
Founded
2022
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
RXO
ADPT
Price
$24.70
$14.01
Analyst Decision
Hold
Strong Buy
Analyst Count
13
9
Target Price
$16.33
$17.78
AVG Volume (30 Days)
3.0M
1.6M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
72.81
63.89
EPS
N/A
N/A
Revenue
$5,742,000,000.00
$276,976,000.00
Revenue This Year
$0.49
$3.98
Revenue Next Year
$6.90
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
26.20
54.77
52 Week Low
$10.43
$8.98
52 Week High
$25.03
$20.76

Technical Indicators

Market Signals
Indicator
RXO
ADPT
Relative Strength Index (RSI) 68.24 52.25
Support Level $15.46 $12.26
Resistance Level N/A $15.27
Average True Range (ATR) 1.71 0.73
MACD 0.41 0.06
Stochastic Oscillator 93.73 58.19

Price Performance

Historical Comparison
RXO
ADPT

About RXO RXO Inc.

RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: